Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
8.25
+0.07 (0.86%)
At close: Dec 20, 2024, 4:00 PM
8.27
+0.02 (0.24%)
After-hours: Dec 20, 2024, 7:53 PM EST
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Vipin Garg |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer and Director |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial and Accounting Officer and Corporate Controller |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 26, 2024 | 8-K | Current Report |
| Aug 15, 2024 | ARS | Filing |
| Aug 15, 2024 | DEF 14A | Other definitive proxy statements |